Study Maps Viral RNA-Protein Links for COVID Drugs
Researchers at UC Riverside and UC San Diego identified RNA-protein interactions that SARS-CoV-2 relies on to replicate.
Updated on Nov. 2, 2026 in Life Sciences
Live Poll
Should the government increase funding for research preparing for future pandemics?
A study co-led by researchers at UC Riverside and UC San Diego identified previously unknown interactions between viral RNA and proteins in SARS-CoV-2. Disrupting these interaction sites significantly reduced viral replication in cell cultures.
Why it matters
SARS-CoV-2 accumulates mutations quickly, which can reduce the effectiveness of treatments designed to recognize its changing features. Targeting conserved interaction sites may offer an approach less vulnerable to that viral drift.
The findings come from cell-culture experiments mapping protein-RNA interactions across the viral genome using enhanced cross-linking and immunoprecipitation (eCLIP). Whether these interaction sites produce comparable effects in living organisms remains untested.
The players
University of California, Riverside
A public research university in Riverside, California, that co-led the study identifying these viral RNA-protein interactions.
University of California, San Diego
A public research university in San Diego, California, that co-led the study alongside UC Riverside scientists.
The details
The researchers used eCLIP to map interactions across the genome, identifying sites involving the RNA-dependent RNA polymerase (RdRp) and the nucleocapsid (N) protein. They designed antisense oligonucleotides to bind these sites, which reduced replication in both Vero cells and human lung cells.
Timeline
2024: A Nature Reviews Microbiology review highlighted broad-spectrum antivirals targeting conserved viral components.
November 2, 2026: Drug Target Review published the study findings.
The Big Picture
The study builds on the eCLIP approach used to map RNA-protein interactions across viral genomes, extending it from basic virology toward antiviral design. It positions RNA-targeted antivirals as a complement to protein-focused drugs that can lose effectiveness as viral variants emerge.
Antiviral approaches targeting conserved viral RNA sites could eventually offer treatment options less affected by viral mutation. Any pharmaceutical application remains years away, pending animal studies and further development.
The takeaway
Stronger antivirals may come from targeting parts of a virus that change least over time. Following research on conserved viral components can help readers track which treatment approaches advance beyond the lab.
Further reading
Explore more research in Life Sciences for context on how molecular biology informs antiviral development.
Source note: This article includes information reported by Drug Target Review.
Live Poll
Should the government increase funding for research preparing for future pandemics?
